Eliminating

Hearing Loss

Affects half of all octogernarians
and is diagnosed in 3 in 1,000 newborns.

Rescue Hearing

RHI has assembled a group of visionary, internationally recognized physicians, scientists and bio engineers who share a common passion for developing therapies for humans suffering from hearing loss. The team is developing therapeutic and diagnostic platforms that will address the most difficult of hearing loss indications.

Rescue Hearing

RHI has assembled a group of visionary, internationally recognized physicians, scientists and bio engineers who share a common passion for developing therapies for humans suffering from hearing loss. The team is developing therapeutic and diagnostic platforms that will address the most difficult of hearing loss indications.

Our Stats

Our Announcements

Over 100 genes identified that can cause deafness.

Rescue Hearing Inc. Announces Addition of Business Advisor Andrew Koopman

GAINESVILLE— October 13, 2020— Rescue Hearing Inc., a team of visionary, internationally recognized physicians, scientists, and bioengineers focused on developing new gene therapies to eliminate hearing loss, announced the addition of Business Advisor Andrew Koopman.

Rescue Hearing Inc. Announces Addition of Drug Development Advisor Dr. Lee Golden

GAINESVILLE— September 24, 2020— Rescue Hearing Inc (RHI), a team of visionary, internationally recognized physicians, scientists, and bioengineers focused on developing new gene therapies to eliminate hearing loss, announced the addition of Drug Development Advisor Dr. Lee Golden.
Stay up to date with RHI. Connect with us on LinkedIn and follow our Twitter for updates and exciting progress

Meet our Medical Specialists

All Scientific Team members are RHI Shareholders
RHI Chief Scientific Advisor University of Kansas Medical Center. Created the first and only gene therapy for hearing loss approved for human clinical trials (Novartis CGF166).

DR. HINRICH STAECKER MD, PHD

RHI Scientific Advisor Mass Eye and Ear Infirmary Harvard Medical School. Dr. Chen’s lab was responsible for generating RHI100’s groundbreaking POC data.

DR. ZHENG-YI CHEN, D. PHIL.

RHI Scientific Advisor Physician Surgeon University of Miami. Expertise in identifying the genetic causes of hearing loss one of the top NIH funded Otolaryngologists.

DR. XUE ZHONG LIU, MD, PHD, FACS

RHI Scientific Advisor Boston Children’s Hospital Harvard Medical School. Expertise in developing vector constructs for the delivery of gene therapies to the inner ear.

Dr.Jeff Holt

RHI Scientific Advisor Hannover Medical School. Expertise in presenting human clinical trial briefing packages to the Paul-Ehrlich-Institute (PEI).

Dr.Anthanasia Warnecke

Latest News

for any inquiries

Reach out to us now
Address

Gainesville, FL

Email

info@rescuehearing.com

Request an appointment

OUR STATS

RHI has produced positive proof of concept data on the first of its 3 gene therapy assets, RHI100

A multi $B asset (Peak revenue 2032)

Entering IND enabling studies phase

Worldwide patent protection through 2041

RHI CSO Dr. Hinrich Staecker is the pioneer of gene therapy for hearing loss as the PI and inventor of the only gene therapy for hearing loss approved for human clinical trial (CGF-166 Novartis).